157 related articles for article (PubMed ID: 37535836)
1. International Bladder Cancer Group Intermediate-risk Nonmuscle-invasive Bladder Cancer Scoring System Predicts Outcomes of Patients on Active Surveillance.
Tan WS; Contieri R; Buffi NM; Lughezzani G; Grajales V; Soloway M; Casale P; Hurle R; Kamat AM
J Urol; 2023 Nov; 210(5):763-770. PubMed ID: 37535836
[TBL] [Abstract][Full Text] [Related]
2. Active Surveillance for Low Risk Nonmuscle Invasive Bladder Cancer: A Confirmatory and Resource Consumption Study from the BIAS Project.
Hurle R; Lazzeri M; Vanni E; Lughezzani G; Buffi N; Casale P; Saita A; Morenghi E; Forni G; Cardone P; Lista G; Colombo P; Peschechera R; Pasini L; Zandegiacomo S; Benetti A; Maffei D; Vavassori I; Guazzoni G
J Urol; 2018 Feb; 199(2):401-406. PubMed ID: 28847481
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic performance and predictive capacity of early urine cytology after transurethral resection of nonmuscle invasive bladder cancer: A prospective study.
Elsawy AA; Harraz AM; Ghobrial FK; Abdullatef M; Ali-El-Dein B
Urol Oncol; 2020 Dec; 38(12):935.e1-935.e8. PubMed ID: 32654947
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS).
Prasad SM; Huang WC; Shore ND; Hu B; Bjurlin M; Brown G; Genov P; Shishkov D; Khuskivadze A; Ganev T; Marchev D; Orlov I; Kopyltsov E; Zubarev V; Nosov A; Komlev D; Burger B; Raju S; Meads A; Schoenberg M
J Urol; 2023 Oct; 210(4):619-629. PubMed ID: 37548555
[TBL] [Abstract][Full Text] [Related]
5. Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non-Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013.
Bree KK; Shan Y; Hensley PJ; Lobo N; Hu C; Tyler DS; Chamie K; Kamat AM; Williams SB
JAMA Netw Open; 2022 Mar; 5(3):e223050. PubMed ID: 35302627
[TBL] [Abstract][Full Text] [Related]
6. Clinical Outcomes of Reresection in Patients with High-Risk Nonmuscle-Invasive Bladder Cancer Treated with
Xu S; Cao P; Wang K; Wu T; Hu X; Chen H; Xu L; Gu J; Wu S; Zhu L; Che X
J Endourol; 2021 Dec; 35(12):1801-1807. PubMed ID: 34235972
[No Abstract] [Full Text] [Related]
7. Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection of Bladder Tumor in Patients with Nonmuscle Invasive Bladder Cancer.
Blute ML; Rushmer TJ; Shi F; Fuller BJ; Abel EJ; Jarrard DF; Downs TM
J Urol; 2015 Nov; 194(5):1214-9. PubMed ID: 26173101
[TBL] [Abstract][Full Text] [Related]
8. Primary Complete Transurethral Resection of Bladder Tumor Using Photodynamic Diagnosis for High-Risk Nonmuscle Invasive Bladder Cancer: Is a Restaging Photodynamic Transurethral Resection Really Necessary?
Tadrist A; Gondran-Tellier B; McManus R; Al Balushi K; Akiki A; Gaillet S; Delaporte V; Karsenty G; Lechevallier E; Boissier R; Baboudjian M
J Endourol; 2021 Jul; 35(7):1042-1046. PubMed ID: 33626963
[No Abstract] [Full Text] [Related]
9. Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non-muscle-invasive Spectrum.
Beijert IJ; Hentschel AE; Bründl J; Compérat EM; Plass K; Rodríguez O; Subiela Henríquez JD; Hernández V; de la Peña E; Alemany I; Turturica D; Pisano F; Soria F; Čapoun O; Bauerová L; Pešl M; Bruins HM; Runneboom W; Herdegen S; Breyer J; Brisuda A; Calatrava A; Rubio-Briones J; Seles M; Mannweiler S; Bosschieter J; Kusuma VRM; Ashabere D; Huebner N; Cotte J; Mertens LS; Claps F; Masson-Lecomte A; Liedberg F; Cohen D; Lunelli L; Cussenot O; El Sheikh S; Volanis D; Côté JF; Rouprêt M; Haitel A; Shariat SF; Mostafid AH; Nieuwenhuijzen JA; Zigeuner R; Dominguez-Escrig JL; Hacek J; Zlotta AR; Burger M; Evert M; Hulsbergen-van de Kaa CA; van der Heijden AG; Kiemeney LALM; Soukup V; Molinaro L; Gontero P; Llorente C; Algaba F; Palou J; N'Dow J; Ribal MJ; van der Kwast TH; Babjuk M; Sylvester RJ; van Rhijn BWG
Eur Urol Oncol; 2023 Apr; 6(2):214-221. PubMed ID: 36670042
[TBL] [Abstract][Full Text] [Related]
10. Safety of active surveillance program for recurrent nonmuscle-invasive bladder carcinoma.
Hernández V; Alvarez M; de la Peña E; Amaruch N; Martín MD; de la Morena JM; Gómez V; Llorente C
Urology; 2009 Jun; 73(6):1306-10. PubMed ID: 19375783
[TBL] [Abstract][Full Text] [Related]
11. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
[TBL] [Abstract][Full Text] [Related]
12. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.
Del Giudice F; Barchetti G; De Berardinis E; Pecoraro M; Salvo V; Simone G; Sciarra A; Leonardo C; Gallucci M; Catalano C; Catto JWF; Panebianco V
Eur Urol; 2020 Jan; 77(1):101-109. PubMed ID: 31699526
[TBL] [Abstract][Full Text] [Related]
13. The importance of transurethral resection of bladder tumor in the management of nonmuscle invasive bladder cancer: a systematic review of novel technologies.
Richards KA; Smith ND; Steinberg GD
J Urol; 2014 Jun; 191(6):1655-64. PubMed ID: 24518761
[TBL] [Abstract][Full Text] [Related]
14. Defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definition.
Lamm D; Persad R; Brausi M; Buckley R; Witjes JA; Palou J; Böhle A; Kamat AM; Colombel M; Soloway M
J Urol; 2014 Jan; 191(1):20-7. PubMed ID: 23973937
[TBL] [Abstract][Full Text] [Related]
15. Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder.
Kluth LA; Xylinas E; Crivelli JJ; Passoni N; Comploj E; Pycha A; Chrystal J; Sun M; Karakiewicz PI; Gontero P; Lotan Y; Chun FK; Fisch M; Scherr DS; Shariat SF
J Urol; 2013 Aug; 190(2):480-6. PubMed ID: 23376707
[TBL] [Abstract][Full Text] [Related]
16. Predicting recurrence of nonmuscle-invasive bladder cancer (Ta-T1): A study based on 477 patients.
Lu M; Chen S; Zhou Q; Wang L; Peng T; Wang G
Medicine (Baltimore); 2019 Jul; 98(28):e16426. PubMed ID: 31305463
[TBL] [Abstract][Full Text] [Related]
17. Surgeon Scorecards Improve Muscle Sampling on Transurethral Resection of Bladder Tumor and Recurrence Outcomes in Patients with Nonmuscle Invasive Bladder Cancer.
Das A; Cohen JE; Ko OS; Jordan BJ; Glaser AP; Auffenberg GB; Meeks JJ
J Urol; 2021 Mar; 205(3):693-700. PubMed ID: 33021430
[TBL] [Abstract][Full Text] [Related]
18. Pathological Outcomes for Patients Who Failed To Remain Under Active Surveillance for Low-risk Non-muscle-invasive Bladder Cancer: Update and Results from the Bladder Cancer Italian Active Surveillance Project.
Hurle R; Colombo P; Lazzeri M; Lughezzani G; Buffi NM; Saita A; Elefante GM; Morenghi E; Forni G; Cardone P; Lista G; Maffei D; Guazzoni G; Casale P
Eur Urol Oncol; 2018 Oct; 1(5):437-442. PubMed ID: 31158085
[TBL] [Abstract][Full Text] [Related]
19. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin.
Sfakianos JP; Kim PH; Hakimi AA; Herr HW
J Urol; 2014 Feb; 191(2):341-5. PubMed ID: 23973518
[TBL] [Abstract][Full Text] [Related]
20. Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial.
Chevli KK; Shore ND; Trainer A; Smith AB; Saltzstein D; Ehrlich Y; Raman JD; Friedman B; D'Anna R; Morris D; Hu B; Tyson M; Sankin A; Kates M; Linehan J; Scherr D; Kester S; Verni M; Chamie K; Karsh L; Cinman A; Meads A; Lahiri S; Malinowski M; Gabai N; Raju S; Schoenberg M; Seltzer E; Huang WC
J Urol; 2022 Jan; 207(1):61-69. PubMed ID: 34433303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
